What is the official website of Novartis Science ?

The official website of Novartis Science is https://www.novartis.com/research-development.

What is Novartis Science's cybersecurity risk score?

Novartis Science has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Science experienced?

According to Rankiteo, Novartis Science currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Science been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Science has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Science have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Science is not certified under SOC 2 Type 1.

Does Novartis Science have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Science does not hold a SOC 2 Type 2 certification.

Does Novartis Science comply with GDPR ?

According to Rankiteo, Novartis Science is not listed as GDPR compliant.

Does Novartis Science have PCI DSS certification ?

According to Rankiteo, Novartis Science does not currently maintain PCI DSS compliance.

Does Novartis Science comply with HIPAA ?

According to Rankiteo, Novartis Science is not compliant with HIPAA regulations.

Does Novartis Science have ISO 27001 certification ?

According to Rankiteo,Novartis Science is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Science operate in ?

Novartis Science operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Science have ?

Novartis Science employs approximately 18 people worldwide.

Does Novartis Science own any subsidiaries ?

Novartis Science presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Science have ?

Novartis Science's official LinkedIn profile has approximately 220,678 followers.

What is the NAICS classification code for Novartis Science ?

Novartis Science is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Science have a Crunchbase profile ?

No, Novartis Science does not have a profile on Crunchbase.

Does Novartis Science have a LinkedIn profile ?

Yes, Novartis Science maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-science.

How many cybersecurity incidents has Novartis Science experienced ?

As of August 9, 2026, Rankiteo reports that Novartis Science has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Science have ?

Novartis Science has an estimated 5,727 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Science faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Science

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novartis Science Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis is an innovative medicines company with research and development at its core. Our R&D engine powers an industry-leading pipeline dedicated to delivering transformative medicines to fight disease, restore possibilities and help people live life on their own terms. See our community guidelines: https://go.novartis.social/4bqbjuA

Novartis Science A.I CyberSecurity Scoring

Scoring History

Novartis Science

Novartis Science CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Science

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Science Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Science

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Science in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Science in 2026.

Incident Types Novartis Science vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Science in 2026.

Incident History - Novartis Science (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Science Subsidiaries

Novartis Science

Pharmaceutical Manufacturing

Website: https://www.novartis.com/research-development

Company Size: 18

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Loading…

Novartis Science Similar Companies

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Loading…

NEWS

Novartis Science CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

February 08, 2026 08:00 AM

Your money online is at risk: UAE’s Cyber Security Council issues warning

The council stressed that steps taken to safeguard personal and financial data across cyberspace reduces the risk of falling victim to cyber...

Read Article

December 17, 2025 08:00 AM

Salesforce’s Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally

SAN FRANCISCO, December 17, 2025--Salesforce (NYSE: CRM), the world's #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global...

Read Article

May 20, 2025 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

March 03, 2025 08:00 AM

February M&A deals: Thermo Fisher, Novartis, and CyberArk Software

Thermo Fisher Scientific Inc. struck a deal with Minnesota-based health care company, Solventum, to buy its purification and filtration business for about $4.1...

Read Article

February 16, 2025 08:00 AM

Ranking the Top 10 High-Paying Tech Jobs in Switzerland in 2025

Explore the top 10 high-paying tech jobs in Switzerland for 2025, including AI, cybersecurity, and cloud computing roles, offering lucrative...

Read Article

December 23, 2024 08:00 AM

Ranking the Top 10 High-Paying Tech Jobs in Switzerland

The Swiss tech industry is thriving, with high demand for roles like Chief Information Officer, Cloud Solutions Architect,...

Read Article

December 23, 2024 08:00 AM

Top 10 Tech Internships Offered in Switzerland

Discover the top 10 tech internships in Switzerland, from Google to Novartis. Learn about opportunities, application tips, and benefits for...

Read Article

October 17, 2024 07:00 AM

Brave new world: Building Europe’s capacities for defence and security R&D

For the first time since the end of the Cold War, the next period of EU politics and policy-making will be dominated by security issues.

Read Article

July 19, 2024 07:00 AM

Pharma companies report various levels of exposure to IT outage caused by CrowdStrike, Microsoft

While the international IT outage caused by cybersecurity specialist CrowdStrike—and subsequently Microsoft—has grounded airlines and forced...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-71983

SUMMARY

MSI Radix AXE6600 router firmware version v781521 contains a command injection vulnerability in the wps.cgi interface that allows remote attackers to execute arbitrary commands by injecting malicious input through the pin2g, pin5g, or pin6g parameters. Attackers can exploit these unsanitized parameters to execute arbitrary commands on the affected device and obtain root privileges.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71502

SUMMARY

CTI-Transmute contains a stored cross-site scripting vulnerability caused by insufficient neutralization of Vue template expression delimiters in server-rendered user-controlled data. An unauthenticated attacker can create a public conversion whose name or description contains a malicious Vue expression using the application's configured [[ ... ]] delimiters. User profile names may provide an additional injection vector. Although Jinja HTML escaping is applied, the resulting value is subsequently included in a DOM region compiled by Vue. Vue interprets the attacker-controlled value as a template expression rather than ordinary text. By accessing the JavaScript Function constructor from within the expression, an attacker can execute arbitrary JavaScript in the security context of the CTI-Transmute origin. The application's nonce-based Content Security Policy does not prevent exploitation because the Vue runtime compiler requires the unsafe-eval policy exception. The malicious payload is stored by the application and executed whenever another user opens an affected page, such as the public conversion detail page. The victim may be a normal user or an administrator. Successful exploitation could allow the attacker to: * Access data available to the victim through the application. * Extract API keys, tokens, or other sensitive information exposed to the page. * Perform authenticated actions using the victim's session. * Modify conversions or other application data. * Escalate the impact by targeting an administrator. A demonstrated payload can use [].constructor.constructor(...) to obtain the JavaScript Function constructor and execute arbitrary code. The regression tests also show that a short first-stage payload could retrieve an uncapped conversion description and evaluate a larger second-stage payload. The patch addresses the vulnerability by registering a global Jinja finalize hook that inserts a zero-width Unicode word joiner inside every Vue delimiter found in server-rendered values. This prevents Vue from recognizing the values as template expressions while preserving their visible representation.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: )

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:A/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-71958

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a buffer overflow vulnerability in the quicksetup.cgi interface. A remote attacker can write overly long strings to the test4, ssid2, and username fields and execute arbitrary commands by crafting a specific payload, or cause the device to crash.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71957

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a buffer overflow vulnerability in the app.cgi interface. A remote attacker can write an overly long string to the netAcc.addlist[].name field and execute arbitrary commands by crafting a specific payload, or cause the device to crash.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71956

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a command injection vulnerability in the app.cgi interface. A remote attacker can inject arbitrary malicious commands into the netDig.ping.dst field, resulting in command execution with root privileges.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…